Abstract
Purpose: To compare the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Design: Retrospective comparative interventional case series. Methods: settings: Nine international uveitis specialty clinics. study population: Forty-eight patients presenting over a three-year period to a study center with acute Vogt-Koyanagi-Harada disease. intervention: Initial treatment with corticosteroid either orally (Oral only group) or intravenously followed by an oral taper (IV+Oral group). main outcome measures: Change in visual acuity with treatment; development of ocular complications, including visually significant cataract, choroidal neovascularization, subretinal fibrosis, fundus pigment migration, nummular hypopigmented lesions, and diffuse fundus depigmentation; use of immunosuppressive therapy. Results: The Oral only group comprised 15 patients (31%) and the IV+Oral group 33 patients (69%). Median follow-up was 15 months. There was no difference in duration of follow-up between groups (P = .234). There was no difference in the change in visual acuity between groups, adjusting for initial visual acuity (P = .402). There were no differences in the rates of development of visually significant cataract, fundus pigmentary changes, or in the rate of use of subsequent immunosuppressive therapy between treatment groups. No patients developed choroidal neovascularization or subretinal fibrosis over the study period. Conclusions: Route of administration of corticosteroid had no detectable effect on change in visual acuity nor on the development of visually significant complications over the study period. Prospective trials are necessary to address speed of resolution and definitively answer outcome questions.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 119-124 |
| Number of pages | 6 |
| Journal | American Journal of Ophthalmology |
| Volume | 142 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jul 2006 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Ophthalmology
Cite this
Evaluation of the Effect on Outcomes of the Route of Administration of Corticosteroids in Acute Vogt-Koyanagi-Harada Disease. / Read, Russell W.; Yu, Fei; Accorinti, Massimo; Bodaghi, Bahram; Chee, Soon Phaik; Fardeau, Christine; Goto, Hiroshi; Holland, Gary N.; Kawashima, Hidetoshi; Kojima, Eri; LeHoang, Phuc; Lemaitre, Claire; Okada, Annabelle A.; Pivetti-Pezzi, Paola; Secchi, Antonio; See, Robert F.; Tabbara, Khalid F.; Usui, Masahiko; Rao, Narsing A.
In: American Journal of Ophthalmology, Vol. 142, No. 1, 07.2006, p. 119-124.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evaluation of the Effect on Outcomes of the Route of Administration of Corticosteroids in Acute Vogt-Koyanagi-Harada Disease
AU - Read, Russell W.
AU - Yu, Fei
AU - Accorinti, Massimo
AU - Bodaghi, Bahram
AU - Chee, Soon Phaik
AU - Fardeau, Christine
AU - Goto, Hiroshi
AU - Holland, Gary N.
AU - Kawashima, Hidetoshi
AU - Kojima, Eri
AU - LeHoang, Phuc
AU - Lemaitre, Claire
AU - Okada, Annabelle A.
AU - Pivetti-Pezzi, Paola
AU - Secchi, Antonio
AU - See, Robert F.
AU - Tabbara, Khalid F.
AU - Usui, Masahiko
AU - Rao, Narsing A.
PY - 2006/7
Y1 - 2006/7
N2 - Purpose: To compare the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Design: Retrospective comparative interventional case series. Methods: settings: Nine international uveitis specialty clinics. study population: Forty-eight patients presenting over a three-year period to a study center with acute Vogt-Koyanagi-Harada disease. intervention: Initial treatment with corticosteroid either orally (Oral only group) or intravenously followed by an oral taper (IV+Oral group). main outcome measures: Change in visual acuity with treatment; development of ocular complications, including visually significant cataract, choroidal neovascularization, subretinal fibrosis, fundus pigment migration, nummular hypopigmented lesions, and diffuse fundus depigmentation; use of immunosuppressive therapy. Results: The Oral only group comprised 15 patients (31%) and the IV+Oral group 33 patients (69%). Median follow-up was 15 months. There was no difference in duration of follow-up between groups (P = .234). There was no difference in the change in visual acuity between groups, adjusting for initial visual acuity (P = .402). There were no differences in the rates of development of visually significant cataract, fundus pigmentary changes, or in the rate of use of subsequent immunosuppressive therapy between treatment groups. No patients developed choroidal neovascularization or subretinal fibrosis over the study period. Conclusions: Route of administration of corticosteroid had no detectable effect on change in visual acuity nor on the development of visually significant complications over the study period. Prospective trials are necessary to address speed of resolution and definitively answer outcome questions.
AB - Purpose: To compare the effect on outcomes of the route of administration of corticosteroids in acute Vogt-Koyanagi-Harada disease. Design: Retrospective comparative interventional case series. Methods: settings: Nine international uveitis specialty clinics. study population: Forty-eight patients presenting over a three-year period to a study center with acute Vogt-Koyanagi-Harada disease. intervention: Initial treatment with corticosteroid either orally (Oral only group) or intravenously followed by an oral taper (IV+Oral group). main outcome measures: Change in visual acuity with treatment; development of ocular complications, including visually significant cataract, choroidal neovascularization, subretinal fibrosis, fundus pigment migration, nummular hypopigmented lesions, and diffuse fundus depigmentation; use of immunosuppressive therapy. Results: The Oral only group comprised 15 patients (31%) and the IV+Oral group 33 patients (69%). Median follow-up was 15 months. There was no difference in duration of follow-up between groups (P = .234). There was no difference in the change in visual acuity between groups, adjusting for initial visual acuity (P = .402). There were no differences in the rates of development of visually significant cataract, fundus pigmentary changes, or in the rate of use of subsequent immunosuppressive therapy between treatment groups. No patients developed choroidal neovascularization or subretinal fibrosis over the study period. Conclusions: Route of administration of corticosteroid had no detectable effect on change in visual acuity nor on the development of visually significant complications over the study period. Prospective trials are necessary to address speed of resolution and definitively answer outcome questions.
UR - http://www.scopus.com/inward/record.url?scp=33745640944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745640944&partnerID=8YFLogxK
U2 - 10.1016/j.ajo.2006.02.049
DO - 10.1016/j.ajo.2006.02.049
M3 - Article
C2 - 16815259
AN - SCOPUS:33745640944
VL - 142
SP - 119
EP - 124
JO - American Journal of Ophthalmology
JF - American Journal of Ophthalmology
SN - 0002-9394
IS - 1
ER -